Glenzocimab
- Generic Name
- Glenzocimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2101829-58-5
- Unique Ingredient Identifier
- 58D9BCH9O0
- Associated Conditions
- -
- Associated Therapies
- -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Target Recruit Count
- 304
- Registration Number
- NCT06437431
Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 260
- Registration Number
- NCT05559398
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Acticor Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT04659109
- Locations
- 🇫🇷
Hôpital de Hautepierre, Strasbourg, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath